Drew Madsen to Remain on Board of DirectorsReschedules Earnings Call For August 13th BROOMFIELD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced the promotion of Joseph D. Christina, the Company’s current President and Chief Operating Officer, to the role of President and Chief Executive Officer and as a member of the Board of Directors, effective August 31, 2025. He will succeed Drew Madsen, who is stepping down as CEO for personal medical reasons but will facilita ...

Core Insights - ScanTech AI Systems Inc. has appointed DeMeakey Williams, Sr. as Senior Vice President of Sales, Business Development, and Investor Relations, effective April 2025, to enhance growth and visibility in the market [2][3][4] - Williams brings over 20 years of experience in revenue scaling and securing government contracts, having previously held senior roles at Pangiam and Smiths Detection, where he secured over $500 million in contracts [3][4] - The company aims to leverage Williams' expertise to drive growth strategies and enhance shareholder value, particularly in the context of increasing demand for AI-powered security solutions [5][6] Company Overview - ScanTech AI specializes in AI-powered CT screening systems designed for aviation, customs, and critical infrastructure, utilizing advanced technology to detect hazardous materials and contraband [6] - The company's solutions are applicable in various high-security environments, including airports, seaports, and government buildings, emphasizing the importance of security in these sectors [6] Market Context - The appointment of Williams comes at a time of rising demand for U.S.-developed AI security solutions, indicating a favorable market environment for ScanTech AI's offerings [3][5] - The company is positioned to capitalize on potential opportunities in nuclear power sectors across the U.S., Canada, and Europe, which may further enhance its market presence [5]

Core Insights - Supernus Pharmaceuticals reported strong operating performance in Q2 2025, driven by significant sales growth of Qelbree and GOCOVRI, which together accounted for 72% of total net sales [2][5] - The company completed the acquisition of Sage Therapeutics on July 31, 2025, enhancing its portfolio in neuropsychiatric conditions with the innovative product ZURZUVAE and a novel CNS discovery platform [3][5] - Supernus is focused on the launch of ONAPGO and the integration of Sage Therapeutics while continuing to drive growth from existing products [2][3] Financial Performance - Qelbree net sales increased by 31% year-over-year to $77.6 million in Q2 2025, with total sales for the first half of 2025 reaching $142.3 million [5][11] - GOCOVRI net sales rose by 16% year-over-year to $36.7 million in Q2 2025, totaling $67.4 million for the first half of 2025 [5][11] - Total revenues for Q2 2025 were $165.5 million, a slight decrease from $168.3 million in Q2 2024, while total revenues for the first half of 2025 were $315.3 million, up from $312.0 million in the same period last year [11][12] Product Pipeline and Developments - The company is conducting a Phase 2b study for SPN-817, a novel AChE inhibitor for epilepsy, with a targeted enrollment of approximately 258 patients [7] - SPN-820, a novel molecule for depression, is set to enter a Phase 2b trial by the end of 2025, targeting around 200 adults with major depressive disorder [8] - SPN-443, a novel stimulant for ADHD/CNS, has completed a Phase 1 pharmacokinetic study, with plans to disclose a lead indication by the end of 2025 [9] Guidance and Future Outlook - Supernus updated its full-year 2025 revenue guidance to $670 - $700 million, reflecting strong first-half performance and the impact of the Sage acquisition [13][20] - The company anticipates combined R&D and SG&A expenses to be between $505 - $530 million for the year [13] - Adjusted operating earnings guidance for 2025 is projected to be between $105 - $135 million, consistent with previous expectations [13][37]

Core Insights - Viasat, Inc. has released its first quarter fiscal year 2026 financial results, which are available on the Investor Relations section of its website [1] Group 1: Financial Results - The financial results for the first quarter of fiscal year 2026 were published in a letter to shareholders [1] Group 2: Conference Call - Viasat will host a conference call on August 5, 2025, at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time, with specific dial-in numbers provided for participants [2] - A live webcast of the conference call will be available, and the call will be archived for approximately one month [3] Group 3: Company Overview - Viasat is a global communications company focused on connecting people and devices worldwide, with operations in 24 countries [4] - The company aims to develop a comprehensive global communications network to provide high-quality, reliable, and secure connections [4] - In May 2023, Viasat completed the acquisition of Inmarsat, enhancing its capabilities and resources [4]

Core Insights - Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections [1][3] - The company will host a conference call on August 12, 2025, at 4:30 p.m. ET to report its financial results for the second quarter of 2025 and provide a business update [1] Company Information - Spero Therapeutics is headquartered in Cambridge, Massachusetts [3] - The company specializes in addressing high unmet needs in the treatment of rare diseases and multi-drug resistant bacterial infections [3] - For further information, Spero Therapeutics maintains an investor relations page on their corporate website [2][3]

SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter ...

Core Insights - LifeMD, Inc. reported strong financial results for Q2 2025, with total revenue increasing by 23% year-over-year to $62.2 million, driven by a 30% increase in telehealth revenue [2][8][9] - The company is expanding its telehealth platform into high-need clinical areas, including a nationwide behavioral health offering and a virtual women's health brand acquisition [4][5] - LifeMD's adjusted EBITDA rose significantly by 223% to $7.1 million, with telehealth adjusted EBITDA increasing by 560% to $3.4 million [5][8][9] Financial Performance - Total revenue for Q2 2025 was $62.2 million, up from $50.7 million in Q2 2024, with telehealth revenue reaching $48.6 million [8][9] - The number of active telehealth subscribers grew by 16% to approximately 297,000 [9][10] - The company generated over $8 million in operating cash flow and exited the quarter with $36.2 million in cash after fully repaying all senior debt [5][9] Operational Highlights - LifeMD launched a nationwide behavioral health offering and acquired a women's health brand to enhance its service offerings [4][5] - The enhanced LifeMD+ membership program was scaled to provide 24/7 urgent and primary care, along with specialty care and wellness products [4][5] - The company reported a gross margin of 88%, slightly down from 90% in the prior year due to revenue mix [9] Guidance and Outlook - LifeMD revised its full-year 2025 guidance for total revenue to a range of $250 million to $255 million, down from previous guidance of $268 million to $275 million [14] - The company expects telehealth revenue for the full year to be in the range of $195 million to $200 million, compared to earlier estimates of $208 million to $213 million [14] - Adjusted EBITDA guidance for the full year was also revised down to a range of $27 million to $29 million from $31 million to $33 million [14]

Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and improved beta-cell function subsequent to the dosing period In a rodent model of T2D, icovamenib in combination with low-dose semaglutide, promoted enhanced glycemic control and weight loss with complete lean mass preservation Icovamenib promoted healthy myotu ...

OKLAHOMA CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Devon Energy Corp. (NYSE: DVN) today reported financial and operational results for the second-quarter 2025. The company also declared its quarterly dividend and provided an updated 2025 outlook. Devon’s earnings release, supplemental financial tables, guidance and related earnings presentation can be accessed via the Investor Relations section of Devon’s website, www.devonenergy.com. The company’s second-quarter conference call will be held at 10:00 a.m. Cen ...

BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales incr ...